Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning capsules; pediatric paracetamol and artificial cow-bezoar and chlorphenamine maleate granules; zhennaoning capsules; compound methionine and choline bitartrate tablets; and compound kushen changyankang tablets. It also provides insulin pens and pen needles; and the Chronic Disease Management Platform, which is a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, the company offers oral anti-diabetic hypoglycemic drugs, such as sitagliptin phosphate, sitagliptin phosphate/metformin hydrochloride, repaglinide, and engagliflozin tablets. Further, it engages in the manufacture, sale, and servicing of plastic building materials and products; technology development of biological products and natural medicines; leasing of workshops; real estate development and sales; second-hand housing transactions; provision of biopharmaceuticals; medical research and experimental development; pharmaceutical retail and wholesale; technical services, technology development, and technical consulting; operation of medical devices and food products; import and export of goods and technologies; internet sales; and health and consulting services. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Tonghua, China.